Gapping down
Other news:
- BIOA -70.1% (Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity)
- COGT -21.3% (Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis; announces updated clinical results from SUMMIT, showcasing powerful symptomatic improvement in nonadvanced systemic mastocytosis patients)
- AGIO -7.5% (Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat)
- ENTA -7.4% (Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus)
- RIOT -6.4% (announces proposed private offering of $500 million of convertible senior notes)
- MRUS -5.6% (Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC)
- OBIO -5.2% (Announces AVIM Therapy Program Presentations at ICI Meeting)
- MOLN -4% (Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024)
- DDOG -3.3% (announces proposed private offering of $775 million of convertible senior notes)
- RMBL -2.4% (entered into that certain Floor Plan Financing Agreement)
- NVDA -1.8% (China investigating NVDA over anti-monopoly laws, according to Bloomberg)